Alexion Pharmaceuticals, Inc.

More than 90% of #RareDiseases have no approved treatment option. We’re determined to change that. Learn how we’re working tirelessly to deliver on that promise for the millions of rare disease patients worldwide: http://spr.ly/6041WUsFH

For us, patient centricity isn't just a goal—it's our guiding principle. If you’re passionate about improving the lives of people affected by #RareDiseases, we’d love to have you on our team. Apply now: http://spr.ly/6042WUSrg

Amyloid light chain (AL) amyloidosis is the most common form of systemic #Amyloidosis. AL can result in significant organ damage and organ failure that can severely impact quality of life and can ultimately be fatal.

Hear from our diagnostics team, Banu Sankaran, Tom Defay and Chathuri Daluwatte, PhD, about promising areas of diagnostic innovation that aim to shorten the path to diagnosis. By harnessing these technologies for diagnostics, we are working to bring new hope to people impacted by rare diseases.

Since 2013, our Blanchardstown, Dublin facility has served as Alexion’s Global Supply Chain and Operations headquarters, enabling us to deliver first-class product to patients around the clock. Watch the video to hear from our Site Lead & Executive Director Maureen Larkin as she shares more about the onsite operations and vibrant team culture there: http://spr.ly/6047WUm21

We are committed to fostering a culture of continuous learning and development by offering ample opportunities for our people to thrive and progress in their careers. Hear from two of our colleagues, whose careers grew in ways they could never have imagined at Alexion.

What gets our Head of Patient Experience and Insights excited about coming to work at Alexion? The shared sense of purpose. Hear how Wendy Erler’s journey to patient advocacy began right in her own backyard–and how it has led her to become a passionate advocate for patients ever since. #LifeAtAlexion

Nick France began his career in rare disease as a pediatrician in clinical care, but he pivoted to industry to make a global impact. Watch this video to hear from him on how we’re advancing the science of genomic medicine.

New research from AstraZeneca in Nature Portfolio demonstrates the transformative potential for gene editing to transform outcomes for people living with rare genetic disorders by addressing their underlying causes.   The new gene editing tool showed enhanced precision to correct genetic mutations, while reducing off-target effects.   This advancement could help accelerate potential new treatments for a range of diseases, including rare conditions—of which 80% are believed to have a genetic cause.   Learn more here: https://lnkd.in/eWkEhvVk

Alexion’s VP CENE Area Head Dana Vigier, MD held a compelling Fireside-Chat accompanied by Oskar Ahlberg from the Swedish patient organization Riksförbundet Sällsynta diagnoser - Rare Diseases Sweden at Reuters Events Pharma in London. They explored how by better understanding and improving the reality of pharma and its engagement with external stakeholders, we enable sustainable long-term partnerships that are for the benefit of patients, healthcare providers and society. The marketing continuum, particularly in orphan disease, shows that there isn’t one customer, yet the power of decision-making lies with few and doesn’t necessarily take into consideration the needs of others. They reflected on the value of inclusion and empowerment, data driven decision making and meaningful stakeholder interactions. #REcustomerEU24 #RareDisease